Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance)

Journal of Clinical Investigation · Published 2026-08-04 · DOI 10.1172/jci205962

Free full text

Authors (9)

Patrick D. Rädler, Brooke M. Felsheim, Aranzazu Fernandez-Martinez, Adam D. Pfefferle, Michele C. Hayward, Baljit Singh, William Sikov, Lisa A. Carey, Charles M. Perou

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Rädler, P., Felsheim, B., Fernandez-Martinez, A., et al. (2026). Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance). Journal of Clinical Investigation. https://doi.org/10.1172/jci205962

Related articles